Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRS-343 + Atezolizumab in HER2+ Solid Tumors
NCT03650348Phase 1Completed
- Sponsor
- Pieris Pharmaceuticals
- Start
- Aug 2018
- Primary completion
- Aug 2022
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cinrebafusp alfa in HER2-positive breast cancer, HER2-positive gastric cancer, HER2-positive bladder cancer and 1 more, sponsored by Pieris Pharmaceuticals. Primary endpoint: Incidence of Dose Limiting Toxicities and Recommended Phase 2 Dose up to 36 months. Started Aug 2018; status: completed.
02
Drugs
cinrebafusp alfa
03
Conditions
HER2-positive breast cancerHER2-positive gastric cancerHER2-positive bladder cancerHER2-positive solid tumor (HER2+)
Beyond the preview
Go deeper on NCT03650348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03650348.